Literature DB >> 22310115

Emergency uncrossmatched transfusion effect on blood type alloantibodies.

Emily Miraflor1, Louise Yeung, Aaron Strumwasser, Terrence H Liu, Gregory P Victorino.   

Abstract

BACKGROUND: Trauma patients receive emergency transfusions of unmatched Type O Rh-negative (Rh-) blood until matched blood is available. We hypothesized that patients given uncrossmatched blood may develop alloantibodies, placing them at risk for hemolytic transfusion reactions (HTRs).
METHODS: Data regarding alloantibody profiles and HTR occurrence were collected from the records of trauma patients at our university-based trauma center who received emergency uncrossmatched blood from July 2008 to August 2010.
RESULTS: A total of 132 patients received 1,570 units of packed red blood cells. Mean injury severity score was 28 ± 1.3. Forty-five (34%) patients died: 27 on hospital day 1; the remaining 18 had no evidence of HTR before death. Four Rh- female patients received Rh+ fresh frozen plasma, but none received Rh+ packed red blood cells. Three Rh- male patients received both Rh+ packed red blood cells and fresh frozen plasma, and one received Rh+ fresh frozen plasma. One patient developed anti-Rh D antibodies. None experienced HTR. One female patient had HTR from reactivation of anamnestic JK antibodies. Thirteen (33%) of 39 patients met criteria for HTR based on urinalysis and 29 (40%) of 72 patients tested met criteria for HTR based on hemoglobin and bilirubin values. Only one patient had confirmed HTR.
CONCLUSION: High rates of injury recidivism in trauma patients increase the likelihood of multiple blood transfusions during their lifetime. Rh- patients who receive Rh+ blood are at risk of developing anti-Rh antibodies, putting them at risk for HTR. The conservation of Rh- blood for use in female patients may be detrimental to Rh- male patients. Laboratory diagnostic criteria for HTR are nonspecific in the trauma population and should be used with caution.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310115     DOI: 10.1097/TA.0b013e31823f0465

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  6 in total

Review 1.  Mortality outcomes in trauma patients undergoing prehospital red blood cell transfusion: a systematic literature review.

Authors:  Gregory S Huang; C Michael Dunham
Journal:  Int J Burns Trauma       Date:  2017-04-15

2.  Unmatched Type O RhD+ Red Blood Cells in Multiple Injured Patients.

Authors:  Sabine Flommersfeld; Carsten Mand; Christian A Kühne; Gregor Bein; Steffen Ruchholtz; Ulrich J Sachs
Journal:  Transfus Med Hemother       Date:  2018-03-07       Impact factor: 3.747

3.  Evaluation of the New Lateral Flow Card MDmulticard® Basic Extended Phenotype in Routine Clinical Practice.

Authors:  Beate Mayer; Julia Müller; María-José Candela-García; Annie-Claude Manteau; Christof Weinstock; Axel Pruß
Journal:  Transfus Med Hemother       Date:  2018-03-09       Impact factor: 3.747

4.  Experience with uncrossmatched blood refrigerator in emergency department.

Authors:  Charles T Harris; Michael Totten; Daniel Davenport; Zhan Ye; Julie O'Brien; Dennis Williams; Andrew Bernard; Leonard Boral
Journal:  Trauma Surg Acute Care Open       Date:  2018-10-09

5.  Safety of Uncrossmatched ABO-Compatible RBCs in Alloimmunized Patients with Bleeding: Data from Two Decades: Results of a Systematic Analysis in 6,109 Patients.

Authors:  Frauke Ringel; Helge Schoenfeld; Said El Bali; Jalid Sehouli; Claudia Spies; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2021-12-08       Impact factor: 4.040

6.  Group A emergency-release plasma in trauma patients requiring massive transfusion.

Authors:  Amory de Roulet; Jeffrey D Kerby; Jordan A Weinberg; Richard H Lewis; Jay P Hudgins; Ira A Shulman; Erin E Fox; John B Holcomb; Karen J Brasel; Eileen M Bulger; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Terence O'Keeffe; Sandro Rizoli; Thomas M Scalea; Martin A Schreiber; Kenji Inaba
Journal:  J Trauma Acute Care Surg       Date:  2020-12       Impact factor: 3.697

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.